Search
ASGCT 2026: Circio's circular RNA work has been advancing and is furthest along in cardiology indications. $35M in new funding will also help accelerate plans to for the eye, CNS, and in vivo CAR-T
Erik Wiklund describes the advantages of circular RNA, and the progress the company has been making since last year's ASGCT. With partnerships and additional funding in hand since then, the company is accelerating its work in multiple dimensions. Coverage brought to you by
12 hours ago
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered...
May 14, 2025
.png){kind=logo}
